BPG is committed to discovery and dissemination of knowledge
Featured Articles
8/26/2019 8:23:20 AM | Browse: 1088 | Download: 1713
Publication Name World Journal of Nephrology
Manuscript ID 46990
Country Greece
ISSN 2220-6124 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Urology & Nephrology
Manuscript Type Minireviews
Article Title The role of mycophenolate in the treatment of antineutrophil cytoplasmic antibody associated vasculitis
Manuscript Source Invited Manuscript
All Author List Maria Koukoulaki and Christos Iatrou
Funding Agency and Grant Number
Corresponding Author Maria Koukoulaki, MD, MPhil, PhD, Manager, Doctor, Doctor, Center for Nephrology "G. Papadakis", General Hospital Of Nikaia - Peiraias "Agios Panteleimon", D. Mantouvalou 3, Nikaia 18454, Piraeus, Greece. mkoukoulaki@gmail.com
Key Words Mycophenolic acid; Mycophenolate mofetil; Mycophenolate sodium; Antineutrophil cytoplasmic antibody associated vasculitis; Microscopic polyangiitis; Granulomatosis with polyangiitis, induction
Core Tip Antineutrophil cytoplasmic antibody associated vasculitis (AAV) is characterized by a remitting - relapsing course of disease that requires long term immunosuppression. Mycophenolic acid has been evaluated as induction and remission maintenance agent in the treatment of AAV as a less toxic agent compared to cyclophosphamide and azathioprine. Mycophenolate has been proven a potent immunosuppressive agent, non-inferior to other available drugs with comparable side effect profile but several studies have shown a higher relapse rate following discontinuation of mycophenolate or in mycophenolate treated subjects. In this review the role of mycophenolate in treatment of AAV is further discussed.
Publish Date 2019-08-21 03:34
Citation Koukoulaki M, Iatrou C. The role of mycophenolate in the treatment of antineutrophil cytoplasmic antibody associated vasculitis. World J Nephrol 2019; 8(4): 75-82
URL https://www.wjgnet.com/2220-6124/full/v8/i4/75.htm
DOI https://dx.doi.org/10.5527/wjn.v8.i4.75
Full Article (PDF) WJN-8-75.pdf
Full Article (Word) WJN-8-75.docx